Biocon Limited (BOM:532523)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Generics	31.68B	30.18B	27.99B	27.64B	23.41B
Generics Growth	4.99%	7.83%	1.23%	18.09%	-0.92%
Biosimilars	104.31B	90.17B	88.24B	55.84B	34.64B
Biosimilars Growth	15.68%	2.19%	58.03%	61.18%	23.72%
Contract Research, Development and Manufacturing Organisation (CRDMO)	37.39B	36.42B	34.89B	31.93B	26.04B
Contract Research, Development and Manufacturing Organisation (CRDMO) Growth	2.64%	4.41%	9.26%	22.61%	19.22%
Inter-Segment Revenue	-4.11B	-	-	-	-
Other Un-Allocable Expenditure / (Income), Net	-	-4.16B	-3.56B	-3.86B	-2.76B
Novel Biologics	-	-	-	192.00M	510.00M
Novel Biologics Growth	-	-	-	-62.35%	385.71%
Total	169.27B	152.62B	147.56B	111.74B	81.84B
Total Growth	10.91%	3.43%	32.05%	36.54%	14.57%

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
India	9.77B	16.08B	16.74B	13.56B
India Growth	-39.27%	-3.93%	23.40%	-0.24%
United States of America	70.42B	64.55B	41.43B	29.95B
United States of America Growth	9.10%	55.80%	38.35%	26.95%
European Union (Including Ireland)	38.48B	35.17B	11.78B	-
European Union (Including Ireland) Growth	9.42%	198.45%	-	-
Rest of The World	33.95B	31.76B	41.79B	21.47B
Rest of The World Growth	6.89%	-24.01%	94.67%	2.62%
Ireland	-	-	-	16.86B
Ireland Growth	-	-	-	26.53%
Total	152.62B	147.56B	111.74B	81.84B
Total Growth	3.43%	32.05%	36.54%	14.57%

Source: S&P Global Market Intelligence.